- Open
- 14.00
- High
- 15.50
- Low
- 13.83
- Close
- 15.49
- Change
- +1.00 (7.14%)
- Volume
- 2,447,618
⌘K
| 28 Apr 2026 | 07:00:11 | FDA Fast Track Designation for iSCIB1+ |
| 2 Apr 2026 | 07:00:05 | Scancell announces CFO transition |
| 29 Jan 2026 | 07:00:07 | Half-year Financial Report |
| 26 Jan 2026 | 07:00:02 | FDA clearance of IND application for iSCIB1+ |
| 31 Oct 2024 | Annual Report and Accounts (to 2024-04-30) | |
| 6 Nov 2023 | Annual Report and Accounts (to 2023-04-30) | |
| 3 Nov 2022 | Annual Report and Accounts (to 2022-04-30) |
Scancell is a company that is creating innovative cancer treatments using its ImmunoBody®, Moditope®, and AvidiMabTM technology platforms. They have several products in development for various types of cancer and are continuously working on new treatments.
| 28 Apr 2026 | 07:00:11 | FDA Fast Track Designation for iSCIB1+ |
| 2 Apr 2026 | 07:00:05 | Scancell announces CFO transition |
| 29 Jan 2026 | 07:00:07 | Half-year Financial Report |
| 26 Jan 2026 | 07:00:02 | FDA clearance of IND application for iSCIB1+ |
| 31 Oct 2024 | Annual Report and Accounts (to 2024-04-30) | |
| 6 Nov 2023 | Annual Report and Accounts (to 2023-04-30) | |
| 3 Nov 2022 | Annual Report and Accounts (to 2022-04-30) |
Scancell is a company that is creating innovative cancer treatments using its ImmunoBody®, Moditope®, and AvidiMabTM technology platforms. They have several products in development for various types of cancer and are continuously working on new treatments.
| 22 Jan 2026 | 07:00:08 | Notice of Results |
| 2 Apr 2026 |
| Scancell CFO to step down as cancer immunotherapy developer names interim replacement |
| 22 Jan 2026 | 07:00:08 | Notice of Results |
| 2 Apr 2026 |
| Scancell CFO to step down as cancer immunotherapy developer names interim replacement |